ACT HPB: The Role of Y90 and Hepatic Artery Infusion (HAI) Chemotherapy in the Management of Unresectable Intrahepatic Cholangiocarcinoma

Saturday, March 12, 2022

11:30 AM – 12:00 PM CST

Location:Chantilly West

Moderator(s)

Michael Lidsky, MD

Assistant Professor of Surgery
Duke University
Durham, NC, United States
Michele Babicky, MD

Surgical Oncologist
The Oregon Clinic
Portland, Oregon, United States

Participants should be aware of the following financial/non-financial relationships:

William Rilling, MD: BD/Bard (Individual(s) Involved: Self): Consultant; Boston Scientific (Individual(s) Involved: Self): Advisor or Review Panel member; Sirtex (Individual(s) Involved: Self): Consultant, Research Grant or Support; Terumo (Individual(s) Involved: Self): Consultant; Varian (Individual(s) Involved: Self): Consultant

Adel Kardosh, MD, PhD: Astellas Pharma Inc. (Individual(s) Involved: Self): Advisor or Review Panel member; Eisai Co., Ltd. (Individual(s) Involved: Self): Advisor or Review Panel member; Natera Inc (Individual(s) Involved: Self): Research Grant or Support

Y90 perspective 11:32 AM 11:42 AM Bill Rilling
HAI perspective 11:42 AM 11:52 AM Adel Kardosh

Presentations:

11:30 AM – 11:32 AM CST

Introductions
Presenter: William Rilling, MD – Medical College of Wisconsin
Presenter: Adel Kardosh, MD, PhD – Oregon Health and Science University
11:32 AM – 11:42 AM CST

Y90 Perspective
Presenter: William Rilling, MD – Medical College of Wisconsin
11:42 AM – 11:52 AM CST

HAI Perspective
Presenter: Adel Kardosh, MD, PhD – Oregon Health and Science University